Fruquintinib and SeRplulimab: Opening New Frontiers in Treating Non-clear Cell Renal Cell Carcinoma

This study is testing a combination of two drugs — fruquintinib (a targeted therapy) and serplulimab (an immunotherapy) — as a first-line treatment for people with a rare, non-clear cell type of kidney cancer that has spread or cannot be removed with surgery. The aim is to see whether this drug combination can shrink tumors and extend survival. **You may be eligible if...** - You are between 18 and 75 years old - You have been diagnosed with metastatic or unresectable non-clear cell kidney cancer - You have not yet received any systemic treatment (no prior chemo, targeted therapy, or immunotherapy) - Your general health is good (ECOG score 0–1) - Your blood counts and organ function meet required levels **You may NOT be eligible if...** - You have had prior systemic cancer treatment - You have uncontrolled hepatitis B or C - You are pregnant or breastfeeding - You have had serious allergic reactions to the study drugs Talk to your doctor to see if this trial is right for you.